Activation of PI3K/AKT pathway: BRAFi monotherapy or D/T combination therapy frequently led to rebound of AKT phosphorylation at an early stage of treatment in melanomas, suggesting that adaptive resistance involving upregulation of the PI3K/AKT pathway is developed and may affect clinical outcomes of BRAFi therapy [42]. The gene discussed is AKT1; the disease is melanoma.